Palatin Technologies, Inc.
USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION

Last updated:

Abstract:

Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

Status:
Application
Type:

Utility

Filling date:

27 Oct 2020

Issue date:

4 Mar 2021